PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Softbank: Systemic risk?

Mon, 07th Sep 2020 15:31

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Danilo Masoni
(danilo.masoni@thomsonreuters.com) and Stefano Rebaudo (stefano.rebaudo@thomsonreuters.com) in
Milan.

SOFTBANK: SYSTEMIC RISK? (1428 GMT)

News of Softbank's large option bets have made investors somewhat more anxious
about the outlook of turbo-charged markets, adding to red flags that have accompanied last
week's tech rout.

Deutsche Bank's Jim Reid speaks of possible "unintended consequences" and makes an analogy
to LTCM, the hedge fund that nearly collapsed in 1998, risking domino effect.

"Experience tells you we haven't heard the last of this story and that unintended
consequences often happen around these type of events," he says in his morning note.

But does Softbank pose any systemic risk?

Saxo Bank's Peter Garnry does not think so, at least for now.

"There has been an explosion in nominal call option exposure from retail investors and the
estimated premium spend over the past month has been around $40 billion dwarfing SoftBank's bets
by a wide margin," he says.

Softbank's debt-servicing metrics look solid and its operations generate healthy cash flows,
Garnry points out, but there's a sort of grey area outside its operating business.

"The vast and complicated balance sheet outside the operating businesses makes the company
somewhat of a 'black box'" he notes.

That's why investors need to be on alert and monitor closely Softbank's 5-year credit
default swaps trading at 180 bps relative to Bloomberg's model of 60 bps, he says.

(Danilo Masoni)

*****

TOP GUN IN U.S. ELECTION YEAR (1342 GMT)

Sustainable? Ethical? Tech and work-from-home stocks? Amid all the hype around those, it's
easy to miss the fact that some of the top equity market performers in recent months have been
--- makers of firearms.

Last week, Smith & Wesson (familiar to fans of Dirty Harry and also the maker of the Walther
PPK pistol beloved of James Bond), reported a 140% jump in Q2 sales versus year-ago levels. The
company's CEO Mark Smith attributed that to "folks who are just fearful of their personal
protection", the FT reported.

And its shares? Up more than 270% in the past six months.

Other firearms manufacturers Sturm Ruger and Vista Outdoor have also seen
their stock rocket around 69% and 240% respectively since early-March. In contrast, Apple is up
81% in this period; the Dow Jones has gained 18% and an MSCI index of U.S. shares run on
ESG tenets has returned 28%.

True, it is a U.S. election year, the time many Americans tend to check they are locked and
loaded against the possibility of tighter gun ownership rules.

In a blog, crypto trading outfit Block-Builders.net notes that trend scores on Google
searchs for "Buy Gun" hit the maximum of one hundred several times this year.

It said searches overwhelmingly originated from the United States where "the explosive
mixture of issues is driving sales upwards: escalating racism debates and scenes of violence in
the wake of them, the fear of a deepening corona crisis and many citizens' concern about more
restrictive gun laws."

(Sujata Rao)

*****

UK REAL ESTATE IS STRONG, BUT WATCH OUT FOR BREXIT (1131 GMT)

Real estate stocks had a very good start today in the UK as well as in the whole continent
after Friday’s fall, but investors are concerned about what it will happen next with a hard
Brexit in the cards.

Europe’s real estate sector index is up 1.5%, while its UK peer rises
1.2%; both are below their session’s highs.

“The big risk is that we see this trend reverse when it comes to year-end and people begin
to consider the impact of a hard Brexit just as the stamp duty holiday draws to an end,” Joshua
Mahony, Senior Market Analyst at IG, says about the UK market.

British house prices jumped by the most since 2016 in August to hit a record high, mortgage
lender Halifax said, adding to signs of a post-lockdown boom in the country's housing market
even as fears grow of a sharp rise in unemployment.

But sterling today is falling against the U.S. dollar and the euro as Brexit talks plunged
into crisis following Britain's threat to override its European Union divorce deal.

(Stefano Rebaudo)

*****

CYCLICALS BET: AUTOS ON A HIGH (1038 GMT)

One sector in Europe is standing out this morning: it's autos.

While the region is showing a quite broad-based rebound, the STOXX Auto index is the
only one that has actually managed to break new ground, up over 2.3% at one point to its highest
since February 2020.

Why that? There's an ongoing "cyclicals bet", as one trader points out, and the tech rout
we've witnessed last week could add fuel to a rotation into the battered end of the market.

Autos are among the worst performers in Europe this year, down around 14%. So there's room
to catch up.

But there's also some good-looking newsflow out of Germany with a Volkswagen
executive telling Welt am Sonntag in an interview published yesterday that VW is in a position
to overtake Tesla in terms of e-car manufacturing by 2023.

That's "positive for sentiment", another trader notes.

(Danilo Masoni)

****

HERE ARE THE WINNERS OF POSITIVE VACCINE NEWS (1010 GMT)

Positive vaccine developments are probably propping up market sentiment today and protecting
global stocks from the U.S. tech selloff and concerns over Softbank's derivatives exposure.

UBS has taken a deeper look and has singled out the potential impact of a Covid vaccine on
European equity markets.

Among countries, Germany is the most affected, followed by the Scandinavian markets and
France, in a ranking that fits with their broader cyclical exposure and their performance since
the market low in March, a UBS research note says.

In sectors, the deep cyclicals and the parts of the market most affected by mobility
restrictions (Transport and Energy) are most sensitive, while banks have failed to get any
benefit and have lagged behind in terms of relative performance since the market low, it adds.

Transport, Tech Hardware and Semis have all outperformed more since the market low than
their beta to vaccine news would suggest.

(Stefano Rebaudo)

*****

OPENING SNAPSHOT: IN POSITIVE TERRITORY, BANKS FLAT (0756 GMT)

European stocks open higher and hold their ground in positive territory despite a fresh
selloff on U.S. tech stocks on Friday continues to worry investors globally.

The STOXX 600 is up 0.9%, in what seems a straight risk-on session with cyclicals
leading gains. The auto sector leads sectoral gains up 1.9%, followed by real estate
up 1.7% and industrial goods and services up 1.4%. The euro Stoxx volatility
index is down almost 3 points at 28.7.

Spain’s banking index turns negative after opening up around 2.7%, while the
European index is flat, after last week rally on M&A negotiations between Bankia
and Caixabank.

Dechra stocks are up 5.9% after its profit beat expectations.

U.S. markets will be closed today for the Labour Day holiday.

SoftBank Group closed down 7% as the conglomerate's bets on equity derivatives tied
to listed technology companies made investors uncomfortable.

(Stefano Rebaudo)

*****

ON THE RADAR: VACCINE DEVELOPMENTS, AB FOODS (0641 GMT)

European stocks are set to open higher as worries about a U.S. tech selloff eased after the
Nasdaq on Friday closed lower but well above its session low with Apple scoring a tiny gain for
the day.

More news on the vaccine front with Australia expecting to receive its first batches after a
deal struck with CSL to manufacture two vaccines - one developed by rival AstraZeneca
and Oxford University, and another developed in CSL's own labs with the University of
Queensland.

Meanwhile Sanofi's chief in France said a vaccine that Sanofi is developing with
Britain's GlaxoSmithKline was likely to be priced at less than 10 euros.

Associated British Foods expects full-year profit at its Primark fashion chain to be
at least at the top end of its previously guided range after trading in its latest quarter
exceeded expectations.

Italy's Treasury wants to find a buyer for Monte dei Paschi di Siena by the end of
the year to help the bailed-out bank to clean up its remaining problem loans.

Italy is close to reaching an agreement over the future of Atlantia unit Autostrade
per l'Italia, Prime Minister Giuseppe Conte said on Saturday in an interview. Progress has been
slowed recently by difficulties in agreeing a valuation for the unit with state lender Cassa
Depositi e Prestiti (CDP), which is due to take control of Autostrade.

Ryanair boss Michael O'Leary's proposed 458,000 euro annual bonus came under fire on
Friday, as an influential investor advisory firm urged shareholders to oppose the package.

(Stefano Rebaudo)

*****

MORNING CALL: IN THE BLACK DESPITE U.S. TECH LOWER (0533 GMT)

European stock futures are in the black despite a new selloff in tech shares on Wall Street
on Friday and Asian stocks on their back foot worried about high valuations.

The Nasdaq on Friday closed lower but well above its session low as selling eased late in
the session, with mega-cap tech companies paring losses though only Apple managed a
tiny gain for the day.

Investors are still uncertain about whether the U.S. is staging just some profit taking or a
massive risk-off move is on its way.

Some traders said a pile of red flags was building up, while mentioning Softbank. Its shares
fell 7% following media reports that the conglomerate made big bets on equity derivatives tied
to listed tech companies.

(Stefano Rebaudo)

*****

More News
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.